Pilot Studies for Development of an HIV Subtype Panel for Surveillance of Global Diversity

Abstract

The continued global spread and evolution of HIV diversity pose significant challenges to diagnostics and vaccine strategies. NIAID partnered with the FDA, WRAIR, academia, and industry to form a Viral Panel Working Group to design and prepare a panel of well-characterized current and diverse HIV isolates. Plasma samples that had screened positive for HIV infection and had evidence of recently acquired infection were donated by blood centers in North and South America, Europe, and Africa. A total of 80 plasma samples were tested by quantitative nucleic acid tests, p24 antigen, EIA, and Western blot to assign a Fiebig stage indicative of approximate time from initial infection. Evaluation of viral load using FDA-cleared assays showed excellent concordance when subtype B virus was tested, but lower correlations for subtype C. Plasma samples were cocultivated with phytohemagglutinin (PHA)-stimulated peripheral blood mononuclear cells (PBMCs) from normal donors to generate 30 viral isolates (50–80% success rate for samples with viral load >10,000 copies/ml), which were then expanded to 10⁷–10⁹ virus copies per ml. Analysis of env sequences showed that sequences derived from cultured PBMCs were not distinguishable from those obtained from the original plasma. The pilot collection includes 30 isolates representing subtypes B, C, B/F, CRF04_cpx, and CRF02_AG. These studies will serve as a basis for the development of a comprehensive panel of highly characterized viral isolates that reflects the current dynamic and complex HIV epidemic, and will be made available through the External Quality Assurance Program Oversight Laboratory (EQAPOL).

Get full access to this article

View all access options for this article.

References

AIDS Epidemic Update: November 2009. www.unaids.org/globalreport/global_report.htm.

LANL HIV Sequence Database. www.HIV.lanl.gov 2011 Los Alamos.

Schmidt

et al. First transmission of human immunodeficiency virus Type 1 by a cellular blood product after mandatory nucleic acid screening in Germany. Transfusion, 2009; 49,9:1836–1844.

Tebit

, Arts

. Tracking a century of global expansion and evolution of HIV to drive understanding and to combat disease. Lancet Infect Dis, 2011; 11,1:45–56.

Taylor

, Hammer

. The challenge of HIV-1 subtype diversity. N Engl J Med, 2008; 359,18:1965–1966.

Sezgin

et al. Effect of host genetics on incidence of HIV neuroretinal disorder in patients with AIDS. J Acquir Immune Defic Syndr, 2010; 54,4:343–351.

Buonaguro

, Tornesello

, Buonaguro

. Human immunodeficiency virus type 1 subtype distribution in the worldwide epidemic: Pathogenetic and therapeutic implications. J Virol, 2007; 81,19:10209–10219.

Soriano

, de Mendoza

. Update on HIV viral-load assays: New technologies and testing in resource-limited settings. Future Virol, 2009; 4,5:423–430.

Edelmann

et al. Improvement of an ultrasensitive human immunodeficiency virus type 1 real-time reverse transcriptase-polymerase chain reaction targeting the long terminal repeat region. Transfusion, 2010; 50,3:685–692.

10.

Henquell

et al. Difficulties in diagnosing group O human immunodeficiency virus type 1 acute primary infection. J Clin Microbiol, 2008; 46,7:2453–2456.

11.

Foglieni

et al. A cluster of human immunodeficiency virus Type 1 recombinant form escaping detection by commercial genomic amplification assays. Transfusion, 2011; 51,4:719–730.

12.

Nubling

et al. Experience of mandatory nucleic acid test (NAT) screening across all blood organizations in Germany: NAT yield versus breakthrough transmissions. Transfusion, 2009; 49,9:1850–1858.

13.

Church

et al. Comparison of the RealTime HIV-1, COBAS TaqMan 48 v1.0, Easy Q v1.2, and Versant v3.0 assays for determination of HIV-1 viral loads in a cohort of Canadian patients with diverse HIV subtype infections. J Clin Microbiol, 2011; 49,1:118–124.

14.

Kline

, Schwarzwald

, Kline

. False negative DNA polymerase chain reaction in an infant with subtype C human immunodeficiency virus 1 infection. Pediatr Infect Dis J, 2002; 21,9:885–886.

15.

Obaro

et al. Failure of serial human immunodeficiency virus type 1 DNA polymerase chain reactions to identify human immunodeficiency virus type 1 clade A/G. Pediatr Infect Dis J, 2005; 24,2:183–184.

16.

Ntemgwa

et al. Discrepancies in assignment of subtype/recombinant forms by genotyping programs for HIV type 1 drug resistance testing may falsely predict superinfection. AIDS Res Hum Retroviruses, 2008; 24,7:995–1002.

17.

Snoeck

et al. Discordances between interpretation algorithms for genotypic resistance to protease and reverse transcriptase inhibitors of human immunodeficiency virus are subtype dependent. Antimicrob Agents Chemother, 2006; 50,2:694–701.

18.

Kuritzkes

. HIV-1 subtype as a determinant of disease progression. J Infect Dis, 2008; 197,5:638–639.

19.

Renjifo

et al. Differences in perinatal transmission among human immunodeficiency virus type 1 genotypes. J Hum Virol, 2001; 4,1:16–25.

20.

Baeten

et al. HIV-1 subtype D infection is associated with faster disease progression than subtype A in spite of similar plasma HIV-1 loads. J Infect Dis, 2007; 195,8:1177–1180.

21.

Daar

et al. Baseline HIV type 1 coreceptor tropism predicts disease progression. Clin Infect Dis, 2007; 45,5:643–649.

22.

Weiss

et al. Acquired immunodeficiency syndrome-related lymphoma: Simultaneous treatment with combined cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy and highly active antiretroviral therapy is safe and improves survival—results of the German Multicenter Trial. Cancer, 2006; 106,7:1560–1568.

23.

Kaslow

, Dorak

, Tang

. Influence of host genetic variation on susceptibility to HIV type 1 infection. J Infect Dis, 2005; 191,Suppl 1:S68–S77.

24.

Huang

, Giesler

, Bremer

. Sequence characterization of the protease and partial reverse transcriptase proteins of the NED panel, an international HIV type 1 subtype reference and standards panel. AIDS Res Hum Retroviruses, 2003; 19,4:321–328.

25.

Brown

et al. Biologic and genetic characterization of a panel of 60 human immunodeficiency virus type 1 isolates, representing clades A, B, C, D, CRF01_AE, and CRF02_AG, for the development and assessment of candidate vaccines. J Virol, 2005; 79,10:6089–6101.

26.

Keele

et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci USA, 2008; 105,21:7552–7557.

27.

Salazar-Gonzalez

et al. Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J Exp Med, 2009; 206,6:1273–1289.

28.

Fiebig

et al. Dynamics of HIV viremia and antibody seroconversion in plasma donors: Implications for diagnosis and staging of primary HIV infection. AIDS, 2003; 17,13:1871–1879.

29.

Erice

et al. Sensitive microculture method for isolation of human immunodeficiency virus type 1 from blood leukocytes. J Clin Microbiol, 1992; 30,2:444–448.

30.

Rolland

et al. Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial. Nat Med, 2011; 17,3:366–371.

31.

Deng

et al. DIVEIN: A web server to analyze phylogenies, sequence divergence, diversity, and informative sites. Biotechniques, 2010; 48,5:405–408.

32.

Giorgi

et al. Estimating time since infection in early homogeneous HIV-1 samples using a poisson model. BMC Bioinformatics, 2010; 11:532.

33.

Vodros

, Fenyo

. Quantitative evaluation of HIV and SIV co-receptor use with GHOST(3) cell assay. Methods Mol Biol, 2005; 304:333–342.

34.

Erali

, Hillyard

. Evaluation of the ultrasensitive Roche Amplicor HIV-1 monitor assay for quantitation of human immunodeficiency virus type 1 RNA. J Clin Microbiol, 1999; 37,3:792–795.

35.

De Bel

et al. Correction of underquantification of human immunodeficiency virus type 1 load with the second version of the Roche Cobas AmpliPrep/Cobas TaqMan assay. J Clin Microbiol, 2010; 48,4:1337–1342.

36.

Elbeik

et al. Quantitative and cost comparison of ultrasensitive human immunodeficiency virus type 1 RNA viral load assays: Bayer bDNA quantiplex versions 3.0 and 2.0 and Roche PCR Amplicor monitor version 1.5. J Clin Microbiol, 2000; 38,3:1113–1120.

37.

Vella

et al. Plasma HIV-1 copy number and in vitro infectivity of plasma prior to and during combination antiretroviral treatment. Antiviral Res, 2000; 47,3:189–198.

38.

Piatak

et al. Viral dynamics in primary HIV-1 infection. Lancet, 1993; 341,8852:1099.

39.

Gorry

et al. Isolation of human immunodeficiency virus type 1 from peripheral blood monocytes. Methods Mol Biol, 2005; 304:25–33.

40.

Sourisseau

et al. Inefficient human immunodeficiency virus replication in mobile lymphocytes. J Virol, 2007; 81,2:1000–1012.

41.

Goonetilleke

et al. The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J Exp Med, 2009; 206,6:1253–1272.

42.

Cuevas

et al. Biological and genetic characterization of HIV type 1 subtype B and nonsubtype B transmitted viruses: Usefulness for vaccine candidate assessment. AIDS Res Hum Retroviruses, 2010; 26,9:1019–1025.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.31 MB